New Drugs Antiplatelets-Antithrombotics - John Fanikos, RPh, MBA ...
New Drugs Antiplatelets-Antithrombotics - John Fanikos, RPh, MBA ...
New Drugs Antiplatelets-Antithrombotics - John Fanikos, RPh, MBA ...
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Most Common Adverse EventsDabigatran 150 mg bidOnly oraltreatmentn = 1226Overalln = 1273WarfarinOnly oraltreatmentn = 1214Overalln = 1266Headache (%) 60 (4.9) 79 (6.2) 64 (5.3) 88 (7.0)Pain in extremity(%)59 (4.8) 64 (5.0) 69 (5.7) 71 (5.6)Nausea (%) 43 (3.5) 49 (3.8) 43 (3.5) 58 (4.6)Diarrhea (%) 46 (3.8) 57 (4.5) 34 (2.8) 38 (3.0)Nasopharyngitis(%)47 (3.8) 50 (3.9) 53 (4.4) 54 (4.3)Dyspnea (%) 33 (2.7) 41 (3.2) 47 (3.9) 53 (4.2)Back pain (%) 42 (3.4) 46 (3.6) 44 (3.6) 50 (3.9)Arthralgia (%) 45 (3.7) 48 (3.8) 30 (2.5) 33 (2.6)Peripheraledema(%)41 (3.3) 43 (3.4) 45 (3.7) 48 (3.8)Dyspepsia (%) 36 (2.9) 39 (3.1) 7 (0.6) 9 (0.7)**p3 x ULN (%) 38 (3.1) 25 (2.1)AST >3 x ULN (%) 42 (3.4) 46 (3.8)ALT >3 x ULN +bilirubin >2 x ULN(%)2 (0.2) 4 (0.4)Schulman S et al. N Engl J Med 2009:361:2342-52RE-LY: A Non-Inferiority TrialPrimary Outcome: Superiority AnalysisP=.34P=.41Blinded Event Adjudication.OpenWarfarinadjusted(INR 2.0-3.0)N=6015Atrial fibrillation≥1 Risk FactorAbsence of contra-indications951 centers in 44 countriesRDabigatranEtexilate110 mg BIDN=6076BlindedDabigatranEtexilate150 mg BIDN=6022•Performed12/05-03/09•Median follow up2.0 years•Follow up 99.9%complete•Mean TTR = 64%(patients onwarfarin)Annual Rate3.0%2.5%2.0%1.5%1.0%0.5%0.0%P